Literature DB >> 1849364

ANF-mediated renal cGMP generation in congestive heart failure.

K B Margulies1, D M Heublein, M A Perrella, J C Burnett.   

Abstract

Previous studies have demonstrated that the biological actions of atrial natriuretic factor (ANF) are mediated via increases in its intracellular second messenger guanosine 3',5'-cyclic monophosphate (cGMP). Because cGMP egresses rapidly from target cells after ANF binding to particulate guanylate cyclase-linked receptors, extracellular cGMP may be a useful biological marker for the action of ANF in vivo under pathophysiological conditions. The present studies tested the hypothesis that the avid sodium retention and renal ANF resistance characteristic of chronic congestive heart failure (CHF) are associated with attenuated renal cGMP responses to ANF. We assessed the natriuretic and cGMP responses to endogenous and exogenous ANF during the evolution of CHF produced by 6 days of rapid ventricular pacing in conscious dogs (n = 6). Simultaneous measurement of plasma and urinary cGMP concentrations allowed determination of the net renal generation of cGMP, an indicator of the renal contribution to total urinary cGMP excretion. In early CHF, increased sodium excretion and renal cGMP production were observed in association with increases in plasma ANF. Exogenous ANF administration (10 micrograms/kg iv) before CHF also produced parallel increases in sodium excretion and renal cGMP production. In more advanced CHF produced by 6 days of pacing, we observed avid sodium retention in association with reversal of earlier increases in renal cGMP production despite progressive increases in circulating ANF. Natriuretic and renal cGMP responses to exogenous ANF were similarly attenuated in chronic CHF. These studies suggest that 1) renal cGMP production is a useful biological marker for the renal natriuretic action of ANF; 2) endogenous ANF contributes to the maintenance of sodium excretion in early CHF via increases in renal cGMP production; and 3) the avid sodium retention and renal ANF resistance in advanced CHF are, in part, linked to attenuated renal cGMP responses to endogenous and exogenous ANF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849364     DOI: 10.1152/ajprenal.1991.260.4.F562

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.

Authors:  Paul M McKie; Alessandro Cataliotti; Guido Boerrigter; Horng H Chen; S Jeson Sangaralingham; Fernando L Martin; Tomoko Ichiki; John C Burnett
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

2.  The role of the neurohormonal system in heart failure.

Authors:  M Komajda; F Pousset; R Isnard; P Lechat
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

Review 3.  Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.

Authors:  H H Chen; A Cataliotti; J C Burnett
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

4.  Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.

Authors:  Noel S Lee; Lori B Daniels
Journal:  Card Fail Rev       Date:  2016-05

Review 5.  Aldosterone receptor blockade in the management of heart failure.

Authors:  Emiliano A Palmieri; Bernadette Biondi; Serafino Fazio
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

6.  Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.

Authors:  Horng H Chen; Brenda K Huntley; John A Schirger; Alessandro Cataliotti; John C Burnett
Journal:  J Am Soc Nephrol       Date:  2006-08-23       Impact factor: 10.121

7.  Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.

Authors:  Candace Y W Lee; Brenda K Huntley; Daniel J McCormick; Tomoko Ichiki; S Jeson Sangaralingham; Ondrej Lisy; John C Burnett
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-12-10

Review 8.  B-type natriuretic peptide: beyond a diagnostic.

Authors:  Fernando L Martin; Horng H Chen; Alessandro Cataliotti; John C Burnett
Journal:  Heart Fail Clin       Date:  2008-10       Impact factor: 3.179

9.  Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.

Authors:  K B Margulies; M A Perrella; L J McKinley; J C Burnett
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.

Authors:  T L Stevens; J C Burnett; M Kinoshita; Y Matsuda; M M Redfield
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.